Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Oct 17, 2016 1:03pm
154 Views
Post# 25351763

RE:RE:LENDEN POSTS INSIDER BOUGHT SHARES ON OPEN MARKET

RE:RE:LENDEN POSTS INSIDER BOUGHT SHARES ON OPEN MARKETHi GV. I'm sure I am missing your point.

I thought this is old news or did this lady receive or purchase a large number of shares. If so it certainly is a vote of confidence for the science.

Also, while the share price is easing down it is still 66% above early September. That share build up in price and volume plus the rescheduled AGMs sure leads me to speculate.

On the Zenith side with zen3694 on mCRPC trial while 4 months into dosing we have not seen any results and I would guess it is too early at this stage.

On the RVX side rvx-208 passed that safety test which is obviously great news but we won't have anything concrete until the futility analysis in 2017.

I can't remember hearing any results from the other trials or things like FDA approvals.

One thing for sure there are lots of things happening.
GLTA
Toinv
Bullboard Posts